Assessing the Current State of Louisiana\u27s Crawfish Fishery: Trends and Challenges in Wild Capture and Aquaculture

Crawfish are found throughout the southern U.S.; however, Louisiana is by far the largest producer. The state’s industry includes harvesting wild crawfish from natural habitats such as bayous, swamps, and marshes, and crawfish reared in outdoor ponds. Although commercial harvest records are available, characterization of Louisiana’s wild capture crawfish fishery in recent years is undocumented, and analysis of environmental variables that could be correlated with annual harvest totals have not yet been explored. Using trip ticket data from the Louisiana Department of Wildlife and Fisheries, I characterized monthly and annual trends within Louisiana basins to assess changes in crawfish harvest over the past 20 years. To understand the wild harvest fishery through changes in hydrological conditions within the Atchafalaya Basin, where more than 80% of wild harvest occurs, I used a linear regression to look at the effects of Atchafalaya River discharge and monthly precipitation accumulation on monthly crawfish harvest from 1999–2020 during months of peak harvest. Louisiana’s crawfish industry is comprised of two unique yet similar components: wild harvest and pond production. Research on crawfish biology and improved methods for pond production has been ongoing since the early 1960’s. Challenges within the crawfish aquaculture industry are documented but of most recent concern is the emergence of white spot syndrome virus (WSSV). WSSV possesses the ability to create mass mortality outbreaks with little notice to farmers. Outbreaks often present in multiple conditions and can be hard to quantify. While white spot syndrome virus was first documented in Louisiana crawfish ponds in 2007, recorded laboratory testing that provides spatial and temporal outbreak data are available beginning in 2020. To better understand WSSV and the challenges it presents within Louisiana’s crawfish industry, I used data from the Louisiana Animal Disease Diagnostic Lab on positive testing ponds. In addition, I recorded pond temperature to assess spatial and temporal trends to better understand the effect of environmental variables on a viral outbreak

A survey of extended radio jets with Chandra and HST

We present the results from an X-ray and optical survey of a sample of 17 radio jets in AGN performed with Chandra and HST. The sample was selected from the radio and is unbiased toward detection at shorter wavelengths, but preferentially it includes beamed sources. We find that X-ray emission is common on kpc-scales, with over half radio jets exhibiting at least one X-ray knot on the Chandra images. The distributions of the radio-to-X-ray and radio-to-optical spectral indices for the detected jets are similar to the limits for the non-detections,suggesting all bright radio jets have X-ray counterparts which will be visible in longer observations. Comparing the radio and X-ray morphologies shows that the majority of the X-ray jets have structures that closely map the radio. Analysis of the SED of the jet knots suggest the knots in which the X-ray and radio morphologies track each other produce X-rays by IC scattering of the Cosmic Microwave Background. The remaining knots produce X-rays by the synchrotron process. Spectral changes are detected along the jets, with the ratio of the X-ray-to-radio and optical-to-radio flux densities decreasing from the inner to the outer regions. This suggests the presence of an additional contribution to the X-ray flux in the jet's inner part, either from synchrotron or IC of the stellar light. Alternatively, in a pure IC/CMB scenario, the plasma decelerates as it flows from the inner to the outer regions. Finally, the X-ray spectral indices for the brightest knots are flat, indicating that the bulk of the luminosity of the jets is emitted at GeV energies, and raising the interesting possibility of future detections with GLAST.Comment: 26 pages, 6 ps figures, 6 jpeg figures (1 replaced); accepted for publication in Ap

AGILE detection of extreme gamma-ray activity from the blazar PKS 1510-089 during March 2009. Multifrequency analysis

We report on the extreme gamma-ray activity from the FSRQ PKS 1510-089 observed by AGILE in March 2009. In the same period a radio-to-optical monitoring of the source was provided by the GASP-WEBT and REM. Moreover, several Swift ToO observations were triggered, adding important information on the source behaviour from optical/UV to hard X-rays. We paid particular attention to the calibration of the Swift/UVOT data to make it suitable to the blazars spectra. Simultaneous observations from radio to gamma rays allowed us to study in detail the correlation among the emission variability at different frequencies and to investigate the mechanisms at work. In the period 9-30 March 2009, AGILE detected an average gamma-ray flux of (311+/-21)x10^-8 ph cm^-2 s^-1 for E>100 MeV, and a peak level of (702+/-131)x10^-8 ph cm^-2 s^-1 on daily integration. The gamma-ray activity occurred during a period of increasing activity from near-IR to UV, with a flaring episode detected on 26-27 March 2009, suggesting that a single mechanism is responsible for the flux enhancement observed from near-IR to UV. By contrast, Swift/XRT observations seem to show no clear correlation of the X-ray fluxes with the optical and gamma-ray ones. However, the X-ray observations show a harder photon index (1.3-1.6) with respect to most FSRQs and a hint of harder-when-brighter behaviour, indicating the possible presence of a second emission component at soft X-ray energies. Moreover, the broad band spectrum from radio-to-UV confirmed the evidence of thermal features in the optical/UV spectrum of PKS 1510-089 also during high gamma-ray state. On the other hand, during 25-26 March 2009 a flat spectrum in the optical/UV energy band was observed, suggesting an important contribution of the synchrotron emission in this part of the spectrum during the brightest gamma-ray flare, therefore a significant shift of the synchrotron peak.Comment: 13 pages, 7 figures, 3 tables. Accepted for publication in Astronomy and Astrophysic

Role of Magmas in protein transport and human mitochondria biogenesis

Magmas, a conserved mammalian protein essential for eukaryotic development, is overexpressed in prostate carcinomas and cells exposed to granulocyte-macrophage colony-stimulating factor (GM-CSF). Reduced Magmas expression resulted in decreased proliferative rates in cultured cells. However, the cellular function of Magmas is still elusive. In this report, we have showed that human Magmas is an ortholog of Saccharomyces cerevisiae Pam16 having similar functions and is critical for protein translocation across mitochondrial inner membrane. Human Magmas shows a complete growth complementation of Δpam16 yeast cells at all temperatures. On the basis of our analysis, we report that Magmas localizes into mitochondria and is peripherally associated with inner mitochondrial membrane in yeast and humans. Magmas forms a stable subcomplex with J-protein Pam18 or DnaJC19 through its C-terminal region and is tethered to TIM23 complex of yeast and humans. Importantly, amino acid alterations in Magmas leads to reduced stability of the subcomplex with Pam18 that results in temperature sensitivity and in vivo protein translocation defects in yeast cells. These observations highlight the central role of Magmas in protein import and mitochondria biogenesis. In humans, absence of a functional DnaJC19 leads to dilated cardiac myophathic syndrome (DCM), a genetic disorder with characteristic features of cardiac myophathy and neurodegeneration. We propose that the mutations resulting in decreased stability of functional Magmas:DnaJC19 subcomplex at human TIM23 channel leads to impaired protein import and cellular respiration in DCM patients. Together, we propose a model showing how Magmas:DnaJC19 subcomplex is associated with TIM23 complex and thus regulates mitochondrial import process

Chandra Observations of Nuclear X-ray Emission from a Sample of Radio Sources

We present the X-ray properties of a sample of 17 radio sources observed with the Chandra X-ray Observatory as part of a project aimed at studying the X-ray emission from their radio jets. In this paper, we concentrate on the X-ray properties of the unresolved cores. The sample includes 16 quasars (11 core-dominated and 5 lobe-dominated) in the redshift range z=0.30--1.96, and one low-power radio-galaxy at z=0.064. No diffuse X-ray emission is present around the cores of the quasars, except for the nearby low-power galaxy that has diffuse emission on a scale and with a luminosity consistent with other FRIs. No high-amplitude, short-term variability is detected within the relatively short Chandra exposures. However, 1510-089 shows low-amplitude flux changes with a timescale of $\sim$25 minutes. The X-ray spectra of the quasar cores are generally well described by a single power law model with Galactic absorption. However, in six quasars we find soft X-ray excess emission below 1.6 keV. Interestingly, we detect an Fe K-shell emission line, consistent with fluorescent Kalpha emission from cold Iron, in one lobe- and two core-dominated sources. The average X-ray photon index for the quasars in the sample is Gamma=1.66 and dispersion, sigma=0.23. The average spectral slope for our sample is flatter than the slope found for radio-quiet quasars and for radio-loud AGNs with larger jet orientations; this indicates that beaming affects the X-ray emission from the cores in our sample of quasars.Comment: 14 pages, 5 figures, Accepted for publication in Astronomy & Astrophysic

AGILE detection of intense gamma-ray emission from the blazar PKS 1510-089

We report the detection by the AGILE (Astro-rivelatore Gamma a Immagini LEggero) satellite of an intense gamma-ray flare from the source AGL J1511-0909, associated with the powerful quasar PKS 1510-089, during ten days of observations from 23 August to 1 September 2007. During the observation period, the source was in optical decrease following a flaring event monitored by the GLAST-AGILE Support Program (GASP) of the Whole Earth Blazar Telescope (WEBT). The simultaneous gamma-ray, optical, and radio coverage allows us to study the spectral energy distribution and the theoretical models based on the synchrotron and inverse Compton (IC) emission mechanisms. AGILE observed the source with its two co-aligned imagers, the Gamma-Ray Imaging Detector and the hard X-ray imager Super-AGILE sensitive in the 30 MeV - 50 GeV and 18 - 60 keV bands, respectively. Between 23 and 27 August 2007, AGILE detected gamma-ray emission from PKS 1510-089 when this source was located about 50 degrees off-axis, with an average flux of (270 +/- 65) x 10^{-8} photons cm^{-2} s^{-1} for photon energy above 100 MeV. In the following period, 28 August - 1 September, after a satellite re-pointing, AGILE detected the source at about 35 degrees off-axis, with an average flux (E > 100 MeV) of (195 +/- 30) x 10^{-8} photons cm^{-2} s^{-1}. No emission was detected by Super-AGILE, with a 3-sigma upper limit of 45 mCrab in 200 ksec. The spectral energy distribution is modelled with a homogeneous one-zone synchrotron self Compton (SSC) emission plus contributions by external photons: the SSC emission contributes primarily to the X-ray band, whereas the contribution of the IC from the external disc and the broad line region match the hard gamma-ray spectrum observed.Comment: 5 pages, 5 figures, accepted for publication in A&

Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial

Background: Semaglutide, a GLP-1 receptor agonist, reduces the risk of major adverse cardiovascular events (MACE) in people with overweight or obesity, but the effects of this drug on outcomes in patients with atherosclerotic cardiovascular disease and heart failure are unknown. We report a prespecified analysis of the effect of once-weekly subcutaneous semaglutide 2·4 mg on ischaemic and heart failure cardiovascular outcomes. We aimed to investigate if semaglutide was beneficial in patients with atherosclerotic cardiovascular disease with a history of heart failure compared with placebo; if there was a difference in outcome in patients designated as having heart failure with preserved ejection fraction compared with heart failure with reduced ejection fraction; and if the efficacy and safety of semaglutide in patients with heart failure was related to baseline characteristics or subtype of heart failure. Methods: The SELECT trial was a randomised, double-blind, multicentre, placebo-controlled, event-driven phase 3 trial in 41 countries. Adults aged 45 years and older, with a BMI of 27 kg/m2 or greater and established cardiovascular disease were eligible for the study. Patients were randomly assigned (1:1) with a block size of four using an interactive web response system in a double-blind manner to escalating doses of once-weekly subcutaneous semaglutide over 16 weeks to a target dose of 2·4 mg, or placebo. In a prespecified analysis, we examined the effect of semaglutide compared with placebo in patients with and without a history of heart failure at enrolment, subclassified as heart failure with preserved ejection fraction, heart failure with reduced ejection fraction, or unclassified heart failure. Endpoints comprised MACE (a composite of non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death); a composite heart failure outcome (cardiovascular death or hospitalisation or urgent hospital visit for heart failure); cardiovascular death; and all-cause death. The study is registered with ClinicalTrials.gov, NCT03574597. Findings: Between Oct 31, 2018, and March 31, 2021, 17 604 patients with a mean age of 61·6 years (SD 8·9) and a mean BMI of 33·4 kg/m2 (5·0) were randomly assigned to receive semaglutide (8803 [50·0%] patients) or placebo (8801 [50·0%] patients). 4286 (24·3%) of 17 604 patients had a history of investigator-defined heart failure at enrolment: 2273 (53·0%) of 4286 patients had heart failure with preserved ejection fraction, 1347 (31·4%) had heart failure with reduced ejection fraction, and 666 (15·5%) had unclassified heart failure. Baseline characteristics were similar between patients with and without heart failure. Patients with heart failure had a higher incidence of clinical events. Semaglutide improved all outcome measures in patients with heart failure at random assignment compared with those without heart failure (hazard ratio [HR] 0·72, 95% CI 0·60-0·87 for MACE; 0·79, 0·64-0·98 for the heart failure composite endpoint; 0·76, 0·59-0·97 for cardiovascular death; and 0·81, 0·66-1·00 for all-cause death; all pinteraction>0·19). Treatment with semaglutide resulted in improved outcomes in both the heart failure with reduced ejection fraction (HR 0·65, 95% CI 0·49-0·87 for MACE; 0·79, 0·58-1·08 for the composite heart failure endpoint) and heart failure with preserved ejection fraction groups (0·69, 0·51-0·91 for MACE; 0·75, 0·52-1·07 for the composite heart failure endpoint), although patients with heart failure with reduced ejection fraction had higher absolute event rates than those with heart failure with preserved ejection fraction. For MACE and the heart failure composite, there were no significant differences in benefits across baseline age, sex, BMI, New York Heart Association status, and diuretic use. Serious adverse events were less frequent with semaglutide versus placebo, regardless of heart failure subtype. Interpretation: In patients with atherosclerotic cardiovascular diease and overweight or obesity, treatment with semaglutide 2·4 mg reduced MACE and composite heart failure endpoints compared with placebo in those with and without clinical heart failure, regardless of heart failure subtype. Our findings could facilitate prescribing and result in improved clinical outcomes for this patient group. Funding: Novo Nordisk